Houston (1)

Recruiting (1)

phase 2 (1)

M.D. Anderson Cancer Center (1)

Iovance Biotherapeutics, Inc. (1)

National Cancer Institute (NCI) (1)

aldesleukin (1)

autologous tumor infiltrating lymphocytes ln-145 (1)

autologous tumor infiltrating lymphocytes ln-145-s1 (1)

cyclophosphamide (1)

fludarabine (1)

ipilimumab (1)

nivolumab (1)

quality-of-life assessment (1)

questionnaire administration (1)

biological (1)

drug (1)

other (1)

Other (1)

Interventional (1)

malignancy in giant cell tumor of bone

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Recruiting

Aug 3, 2022